Neuropace Inc (NPCE)vsStryker Corporation (SYK)
NPCE
Neuropace Inc
$12.93
-0.69%
HEALTHCARE · Cap: $443.13M
SYK
Stryker Corporation
$304.00
+2.55%
HEALTHCARE · Cap: $113.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 24048% more annual revenue ($25.84B vs $106.99M). SYK leads profitability with a 14.4% profit margin vs -17.9%. SYK earns a higher WallStSmart Score of 67/100 (B-).
NPCE
Avoid27
out of 100
Grade: F
SYK
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-18.0%
Fair Value
$12.34
Current Price
$12.93
$0.59 premium
Margin of Safety
-33.2%
Fair Value
$229.90
Current Price
$304.00
$74.10 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
17.1% revenue growth
Large-cap with strong market position
Strong operational efficiency at 27.0%
Earnings expanding 44.1% YoY
Generating 1.1B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 36.9x book value
ROE of -160.8% — below average capital efficiency
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NPCE
The strongest argument for NPCE centers on Revenue Growth. Revenue growth of 17.1% demonstrates continued momentum.
Bull Case : SYK
The strongest argument for SYK centers on Market Cap, Operating Margin, EPS Growth. PEG of 1.29 suggests the stock is reasonably priced for its growth.
Bear Case : NPCE
The primary concerns for NPCE are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 5.88 is elevated, increasing financial risk.
Bear Case : SYK
The primary concerns for SYK are P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
NPCE profiles as a growth stock while SYK is a value play — different risk/reward profiles.
NPCE carries more volatility with a beta of 1.87 — expect wider price swings.
NPCE is growing revenue faster at 17.1% — sustainability is the question.
SYK generates stronger free cash flow (1.1B), providing more financial flexibility.
Bottom Line
SYK scores higher overall (67/100 vs 27/100). Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Neuropace Inc
HEALTHCARE · MEDICAL DEVICES · USA
NeuroPace, Inc. is a medical device company in the United States. The company is headquartered in Mountain View, California.
Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?